Ectopic Eruption of Maxillary First Permanent Molars: Preliminary Results of Prevalence and Dentoskeletal Characteristics in Spanish Paediatric Population.

The ectopic eruption of the maxillary first permanent molar (EEM) is a local alteration of dental eruption with a multifactorial aetiology. The aims of our study were to determine the prevalence of the EEM in children and to analyse whether there is a relationship between EEM and dento-skeletal characteristics. A total of 322 children were analysed with the Ricketts cephalometric study and descriptive and analytical statistical analysis was carried out. The prevalence of EEM was 8.7%, with no statistically significant differences regarding gender or location, but a higher prevalence in the 7-year-old age group (18.8%) and bilateral EEM was more prevalent than unilateral EEM (p < 0.05). The most frequent findings were a shortened anterior cranial base, a retroposition of the maxilla and a distal position of the upper permanent first molar in relation to the pterygoid vertical in children with EEM. No statistically significant differences were found regarding the cephalometric parameters except a decreased palatal plane in the bilateral EEM group and a distal upper incisor position in the EEM group (p < 0.05). In conclusion, the prevalence of the EEM was 8.7%, more frequently bilateral, and significantly in seven-year-old patients. Children with bilateral EEM have decreased palatal plane values and a more posterior position of the upper incisor.

Treatment Outcomes of Implant-Supported Maxillary Obturator Prostheses in Patients with Maxillary Defects: A Systematic Review.

PURPOSE: To systematically review the current evidence on clinical and patient-reported outcomes of implant-supported palatal obturator prostheses. MATERIALS AND METHODS: An electronic search of the PubMed, Web of Science, and Cochrane databases was carried out in June 2019. The titles and abstracts of all articles were screened by two independent reviewers. The references of the subsequently selected studies were further screened for potential articles. Assessment of the selected full texts was performed independently according to established inclusion and exclusion criteria. The quality of the selected studies was determined using the Newcastle-Ottawa scale. Interrater agreement on study selection was calculated using Cohen kappa statistic. RESULTS: The search yielded a total of 2,797 records. Ten studies were selected for data extraction, with a Cohen kappa value of 0.856. Five studies were prospective, and five were retrospective. The survival rates for conventional implants ranged from 21.42% to 100%, whereas for zygomatic implants, the survival rates varied from 30% to 100%. Four studies reported prosthodontic complications, with screw loosening being the most common. Patient quality of life (QoL) was analyzed in six studies. CONCLUSION: In spite of the limitations of the present review, it can be concluded that the clinical outcomes are acceptable in terms of survival rates, implant and prosthodontic complications, and QoL associated with implant-supported maxillary obturator prostheses. QoL of implant-supported prostheses in these patients are acceptable. The general study design was not homogenous between studies.

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis

BACKGROUND: The aim of the present study was to analyse the incidence, risk ratio (RR) and prognoses of two types of medication-related osteonecrosis of the jaws (MRONJ): denosumab-related osteonecrosis of the jaws (DRONJ) and Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ) in cancer patients under treatment with deno-sumab or zoledronic acid (ZA). MATERIAL AND METHODS: An electronic and manual search was conducted for randomized controlled trials (RCTs) until May 2019. Assessment of the identified studies, risk of bias and data extraction were performed independently by two reviewers. The incidence of DRONJ and BRONJ and the RR to develop MRONJ were calculated at 1 year, 2 years and 3 years of exposure. It was also calculated the odds ratio (OR) of their respective prognoses. They were calculated normalizing the values of the individual studies to 1 year, 2 years or 3 years when necessary through robust regression models using a statistical program. RESULTS: From 1.277 references identified, 8 RCTs were included, which comprised a total of 13.857 patients with a variety of neoplasms. The incidence of DRONJ in cancer patients under treatment with denosumab ranged from 0.5 to 2.1% after 1 year, 1.1 to 3.0% after 2 years, and 1.3 to 3.2% after 3 years of exposure. The incidence of BRONJ in cancer patients under treatment with ZA ranged from 0.4 to 1.6% after 1 year of exposure, 0.8 to 2.1% after 2 years, and 1.0 to 2.3% after 3 years of exposure. Statistically significant differences were found between de-nosumab and ZA in the risk of developing MRONJ after 1, 2 and 3 years of exposure. Nevertheless, there were no significant differences in terms of patient prognosis. CONCLUSIONS: Denosumab is associated with a significantly higher risk of developing MRONJ compared to ZA. Nevertheless, no differences were found in its prognoses

No disponible

Effect of Periapical Diseases in Development of MRONJ in Immunocompromised Mouse Model.

OBJECTIVES: This study aimed to assess the effect of zoledronic acid on an immunocompromised mice model with periapical disease. MATERIALS AND METHODS: Thirty C57BL/6N mice were randomly divided into three groups (N = 10). All animals were subjected to bilateral ovariectomy (OVX) and then treated with saline (Veh), zoledronic acid (ZA), or concomitant zoledronic acid and dexamethasone (ZA/Dx) for 12 weeks. Eight weeks after starting drug administration, pulpal exposure was conducted on the lower left first molar. Four weeks after pulpal exposure, all mice were sacrificed and the mandibles were collected for radiological and histological examinations. RESULTS: Microcomputed tomography (µ-CT) examination showed significantly reduced periapical bone resorption in the ZA/Dx group and decreased periodontal bone resorption in both ZA and ZA/Dx groups. Higher bone mineral density (BMD) and strengthened microstructure were found in ZA and ZA/Dx groups. More empty lacunae were found in ZA and ZA/Dx groups. CONCLUSIONS: Apical periodontitis aggravates MRONJ under immunocompromised circumstances. Concurrent use of ZA and steroids inhibits alveolar bone resorption but increases the risk of developing MRONJ.

Tratamiento del tumor odontogénico queratoquístico: revisión sistemática / Surgical treatment of odontogenic keratocystic tumor: a systematic review

Introducción: El queratoquiste odontogénico (QO) se considera hoy en día un tumor odontogénico benigno. A pesar de esto, tiene un carácter agresivo debido fundamentalmente a su potencial expansivo a nivel local y a su alta capacidad de recidiva. Actualmente, existen diferentes variedades terapéuticas que se relacionan directamente con las tasas de recurrencia de este tipo de tumor. Objetivo: El objetivo de este estudio es analizar las tasas de recurrencia de las diferentes modalidades de tratamiento del QO. Material y método: Siguiendo las recomendaciones PRISMA se realizó una revisión sistemática en diferentes bases de datos analizando las tasas de recurrencia de distintas opciones terapéuticas del QO. Resultados: El porcentaje medio de recurrencia de los 11 artículos revisados fue del 26,8 %, siendo la resección en bloque el tratamiento con menores tasas de recidiva (0 %) y la marsupialización el tratamiento que mayor porcentaje de recurrencia presentó (45,8 %). Discusión: La recidiva se relaciona directamente con la posibilidad de que restos del tumor o del epitelio que lo rodea puedan permanecer en la cavidad después del tratamiento. Por ello, la resección en bloque es el tratamiento que menos recurrencia presenta. Sin embargo, la agresividad de esta modalidad terapéutica no está justificada en todos los casos, existiendo otras variantes muy eficaces como la enucleación, ya sea sola o en combinación con terapias coadyuvantes como la aplicación de solución de Carnoy. Conclusiones: El tratamiento resectivo presenta las menores tasas de recurrencia, aunque se considera que el QO puede ser abordado de una manera más conservadora dada su naturaleza benigna

Introduction: The odontogenic keratocystic (OK) is considered nowadays as a benign odontogenic tumor. Nevertheless, it has an aggressive nature due mainly to its local expansive potential and its high recurrence rate. Currently, there are different therapeutic approaches that are directly related to the recurrence rates of this type of tumor. Objective: The objective of this study is to analyze the recurrence rates of the different treatment modalities of the OK. Material and method: Following PRISMA recommendations, it was perfomed a systematic review in different databases analyzing the recurrence rates of different therapeutic options of the OK. Results: The average percentage of recurrence of the 11 articles reviewed was of 26,8 %, being resection the treatment with lower recurrence rates (0 %) and marsupialization the treatment with the highest percentage of recurrence (45,8 %). Discussion: Recurrence is directly related to the possibility that parts of the epithelium may remain in the cavity after treatment. Therefore, resection is the treatment with the least recurrence. However, the aggressiveness of this therapeutic modality is not justified in all cases. There are other very effective variants such as enucleation either alone or in combination with adjuvant therapies such as Carnoy's solution application. Conclusions: Resective treatment has the lowest recurrence rates although it is considered that the OK can be approached in a more conservative way due to its benign nature

Bacteriophage Sf6 Tailspike Protein for Detection of Shigella flexneri Pathogens.

Bacteriophage research is gaining more importance due to increasing antibiotic resistance. However, for treatment with bacteriophages, diagnostics have to be improved. Bacteriophages carry adhesion proteins, which bind to the bacterial cell surface, for example tailspike proteins (TSP) for specific recognition of bacterial O-antigen polysaccharide. TSP are highly stable proteins and thus might be suitable components for the integration into diagnostic tools. We used the TSP of bacteriophage Sf6 to establish two applications for detecting Shigella flexneri (S. flexneri), a highly contagious pathogen causing dysentery. We found that Sf6TSP not only bound O-antigen of S. flexneri serotype Y, but also the glucosylated O-antigen of serotype 2a. Moreover, mass spectrometry glycan analyses showed that Sf6TSP tolerated various O-acetyl modifications on these O-antigens. We established a microtiter plate-based ELISA like tailspike adsorption assay (ELITA) using a Strep-tag®II modified Sf6TSP. As sensitive screening alternative we produced a fluorescently labeled Sf6TSP via coupling to an environment sensitive dye. Binding of this probe to the S. flexneri O-antigen Y elicited a fluorescence intensity increase of 80% with an emission maximum in the visible light range. The Sf6TSP probes thus offer a promising route to a highly specific and sensitive bacteriophage TSP-based Shigella detection system.

New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery

Background: Thrombotic disorders remain a leading cause of death in the Western World. For decades, vitamin K antagonists used in the prevention of this pathology, such as warfarin or sintrom, were the only oral agents available for long-term anticoagulation, in spite of their disadvantages. Material and Methods: An electronic database search was carried out on MedLine and The Cochrane Library Plus, without restrictions on the type of study nor dates, in English and Spanish. Abstracts were reviewed, and complete articles if necessary, considering all articles that included recommendations on DOACs and oral surgery. Results: In recent years, the so-called "new oral anticoagulants" have been introduced in clinical practice to treat those patients whose medical conditions require long-term anticoagulant treatment, replacing traditional oral anticoagulants. Conclusions: The new oral anticoagulants represent new therapeutic options, with a number of advantages such as poor interaction with food, minor drug interactions, and do not require periodic dose adjustments or routine controls. The purpose of this review is to establish an update on the new oral anticoagulants: Dabigatran, Rivarozaban, Apixaban and Edoxaban (AU)

No disponible

Surgical complications in zygomatic implants: A systematic review

BACKGROUND: The use of zygomatic implants in the prosthetic rehabilitation of the patient with severe maxillary bone atrophy is another therapeutic alternative, not exempt from complications. The main objective of this review is to analyze and describe the most frequent surgical complications associated with the use of zygomatic implants. MATERIAL AND METHODS: An electronic database search on PubMed, along with a manual search, without taking into account date nor language, was undertaken by two observers, selecting studies that comprised a study period from 6 to 12 months, any type of clinical trial, and series that included a follow-up and/or review period during the aforementioned margin, that mentioned at least two types of complications. RESULTS: Out of the initial search that yielded 455 studies, 67 were considered potentially relevant for the present study, out of which 14 were finally selected. Out of the most frequent surgical complications, sinusitis (3,9%) and failure in osseointegration (2,44%) are highlighted. CONCLUSIONS: The analysis of the results shows that the most frequent complications are sinusitis and failure in osseointegration of the zygomatic implant. However, a standardised data collection system for the data on complications is needed